Clinical trial · Observational
Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer
Real World Study to Evaluate the Efficacy and Resistant Mechanism of Erlotinib/Gefitinib Combined With Bevacizumab in First Line EGFR Mutation Positive Advanced Non-aquamous Non-small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to explore the efficacy and safety of Erlotinib/Gefitinib combined with bevacizumab in the real world for advanced non-squamous cell lung cancer with EGFR mutation, explore new drug resistance mechanisms under the A+T regimen and consistency between plasma and tissue detection driving genes, and finally assess the predictive value of plasma dynamic detection driving gene mutation profiles in predicting disease. The role of disease progression risk.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Erlotinib/Gefitinib combined with Bevacizumab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cohorts 1
- description
- patients with EGFR mutation-positive who received treatment of Erlotinib/Gefitinib Combined With Bevacizumab
- interventionNames
- Drug: Erlotinib/Gefitinib combined with Bevacizumab
Primary outcomes (1)
- measure
- PFS
- timeFrame
- Approximately 1 years
- description
- Progression free survival
Secondary outcomes (2)
- measure
- OS
- timeFrame
- Approximately 1 years
- description
- Overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * EGFR mutation(19del/L858R) * advanced non-saquamous non-small cell lung cancer * primary treatment of first diagnosis * performance status（0-1) Exclusion Criteria: * other genes mutation * saquamous
References
Publications (0)
Data not yet available